Key facts
- Cordance Medical’s last known valuation is $24.0M (Feb 2024).
- It has raised $20.3M; the latest was Seed Round ($8.0M) in Nov 2025.
- Notable investors include Creative Destruction Lab, US National Science Foundation, Impact Assets, University of Toronto, Endless Frontier Labs — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Cordance Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Cordance Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cordance Medical
Developer of a non-invasive, outpatient-focused ultrasound system designed to temporarily and safely open the blood-brain barrier. The company's device offers low-power ultrasound that reversibly opens the blood-brain barrier precisely where it is needed to allow a new wave of diagnostic and therapeutic opportunities for patients to get relief from brain cancer and other neurological diseases, enabling patients to get systemically administered drugs for the targeted brain regions.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2018
- Employees
- 10
- Website
- cordancemedical.com/
- Ownership
- Privately Held (backing)
Cordance Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cordance Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cordance Medical in its N-PORT filings yet. We sweep new filings monthly.